Requirement of N-terminal amino acid residues of gp41 for human immunodeficiency virus type 1-mediated cell fusion
about
A bidirectional SF2/ASF- and SRp40-dependent splicing enhancer regulates human immunodeficiency virus type 1 rev, env, vpu, and nef gene expressionThe role of eukaryotic subtilisin-like endoproteases for the activation of human immunodeficiency virus glycoproteins in natural host cellsExtended base pair complementarity between U1 snRNA and the 5' splice site does not inhibit splicing in higher eukaryotes, but rather increases 5' splice site recognitionThe hepatitis B virus PRE contains a splicing regulatory element.Membrane interface-interacting sequences within the ectodomain of the human immunodeficiency virus type 1 envelope glycoprotein: putative role during viral fusionCorrect mRNA processing at a mutant TT splice donor in FANCC ameliorates the clinical phenotype in patients and is enhanced by delivery of suppressor U1 snRNAs.Conformational partitioning of the fusion peptide of HIV-1 gp41 and its structural analogs in bilayer membranes.Oligomerization of fusogenic peptides promotes membrane fusion by enhancing membrane destabilizationOligomeric beta-structure of the membrane-bound HIV-1 fusion peptide formed from soluble monomers.The sequence complementarity between HIV-1 5' splice site SD4 and U1 snRNA determines the steady-state level of an unstable env pre-mRNA.The strength of the HIV-1 3' splice sites affects Rev function.Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapyLipid membrane fusion induced by the human immunodeficiency virus type 1 gp41 N-terminal extremity is determined by its orientation in the lipid bilayerHuman immunodeficiency virus type 1 envelope glycoprotein oligomerization requires the gp41 amphipathic alpha-helical/leucine zipper-like sequenceExon 1 leader sequences downstream of U5 are important for efficient human immunodeficiency virus type 1 gene expressionThe membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine designConformational mapping of the N-terminal peptide of HIV-1 gp41 in lipid detergent and aqueous environments using 13C-enhanced Fourier transform infrared spectroscopyMutational analysis of the fusion peptide of Moloney murine leukemia virus transmembrane protein p15EMembrane structure of the human immunodeficiency virus gp41 fusion domain by molecular dynamics simulation.A novel approach to describe a U1 snRNA binding site.Solid-state NMR spectroscopy of human immunodeficiency virus fusion peptides associated with host-cell-like membranes: 2D correlation spectra and distance measurements support a fully extended conformation and models for specific antiparallel strandChemical shift assignment and structural plasticity of a HIV fusion peptide derivative in dodecylphosphocholine micellesSolid-state nuclear magnetic resonance measurements of HIV fusion peptide to lipid distances reveal the intimate contact of beta strand peptide with membranes and the proximity of the Ala-14-Gly-16 region with lipid headgroups.Insights into the selective activation of alternatively used splice acceptors by the human immunodeficiency virus type-1 bidirectional splicing enhancer.Efficient Fusion at Neutral pH by Human Immunodeficiency Virus gp41 Trimers containing the Fusion Peptide and Transmembrane Domain.Fusogenic activation of gp41
P2860
Q24563281-9C48D324-79BC-4992-8858-96FD3ED44BD5Q24678833-D0225D23-F81E-49D0-AFDE-6E8386C6D580Q24812684-6CE8E65B-B812-4202-B807-EAAE2CE8B0EDQ25255938-23EF09C4-5203-49C1-861F-F21C898F1BA1Q27469690-54CB2BEA-B21C-41FE-9552-79C735A3B6B3Q34169373-02F9D8A6-EAE4-4FD3-839E-EF8327856966Q34179319-6C0B721F-1264-4682-AACF-77580A0E1CDAQ34184290-6793ABDC-7E91-4F37-8CB4-EA74931C39D4Q34187142-ADF0139A-9CD5-49DF-A907-7FE2D7A230F0Q34363471-EF21B8EC-70B8-4FAF-A81A-3066F856A722Q35220043-D56905F5-4983-4B3D-B7E5-B4F6C98FDAEEQ35615810-FB3C3A31-44F6-4F6B-BF05-33617E01811FQ35853574-6658BC76-52F1-46DA-B35E-0B78DFEF6392Q35878159-76A6F44C-C154-4C59-BD1A-5B35C0D7CDBAQ35880472-6635B5BE-D646-4AB4-9CD8-C53200465E61Q36497712-1613C2CD-2DEE-4897-9803-029AADD78524Q36519512-08BAAD3B-F8B7-4758-A2BC-0E94893E66B0Q39642472-3FD849BA-8FA1-4C83-A044-1382A0BAFBA8Q40209529-BF23A721-9F2A-4A0C-949E-9C1445B58287Q40315328-7CD59CED-60F2-486F-9EEC-AC8C4DB88CF8Q41534544-6BAA9757-DE12-4E82-AE43-C0B87E1549AAQ41855628-3F4742D5-9E1B-4640-9F01-9BFB8AA3EAF4Q42009823-7090E067-7648-4744-AF34-043FA10D8A73Q43029724-6947EEAD-53E7-4B89-B5E1-2ED7C32F32A7Q47551930-A424C0A9-2BCF-4038-8136-BFF8A062F8DBQ50289261-FBF080AA-8E09-4CA7-9A79-68831D3A940A
P2860
Requirement of N-terminal amino acid residues of gp41 for human immunodeficiency virus type 1-mediated cell fusion
description
1995 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հունիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1995
@ast
im Juni 1995 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1995/06/01)
@sk
vědecký článek publikovaný v roce 1995
@cs
wetenschappelijk artikel (gepubliceerd op 1995/06/01)
@nl
наукова стаття, опублікована в червні 1995
@uk
مقالة علمية (نشرت في يونيو 1995)
@ar
name
Requirement of N-terminal amin ...... us type 1-mediated cell fusion
@ast
Requirement of N-terminal amin ...... us type 1-mediated cell fusion
@en
Requirement of N-terminal amin ...... us type 1-mediated cell fusion
@nl
type
label
Requirement of N-terminal amin ...... us type 1-mediated cell fusion
@ast
Requirement of N-terminal amin ...... us type 1-mediated cell fusion
@en
Requirement of N-terminal amin ...... us type 1-mediated cell fusion
@nl
prefLabel
Requirement of N-terminal amin ...... us type 1-mediated cell fusion
@ast
Requirement of N-terminal amin ...... us type 1-mediated cell fusion
@en
Requirement of N-terminal amin ...... us type 1-mediated cell fusion
@nl
P2093
P2860
P1433
P1476
Requirement of N-terminal amin ...... us type 1-mediated cell fusion
@en
P2093
P2860
P304
P577
1995-06-01T00:00:00Z